Immusoft Corporation

B cells as biofactories for therapeutic protein delivery for rare diseases

[Immusoft Corporation @immusoft]

Thanks @WIRED @emilylmullin for speaking with our CEO Sean Ainsworth about the first engineered B cell therapy dosed in human trials: 🧬🧬🧬

https://t.co/NUzn8YFKIC

[Immusoft Corporation @immusoft]

We’re excited to announce our presentation at @WORLDSymposia 2024 Conference, held in San Diego, February 4-9. WORLDSymposium is the largest international gathering of lysosomal disease researchers.

Read the full release:

https://t.co/nqP55LjHoJ

[Immusoft Corporation @immusoft]

.@DDWJournal covers our recent first patient dosed using the world’s first engineered B cell therapy. 🧬🧬🧬

https://t.co/QKTyv6Vfrb

[Immusoft Corporation @immusoft]

.@TrialsArena covers our first patient dosed in #MPS1:

https://t.co/tTm7Wmr20e

[Becker's Hospital Review @BeckersHR]

A trial by Seattle-based Immusoft, a biotech company, said it is the first to genetically engineer B cells and test them in a patient, Wired reported Dec. 15. https://t.co/Vei9fqtX7o

[Immusoft Corporation @immusoft]

@jan_nolta @CIRMnews Thank you!

[California Institute for Regenerative Medicine @CIRMnews]

CIRM is proud to support @immusoft's groundbreaking B cell therapy trial for MPS I and other diseases.

"Our goal is always to move the most promising research forward as fast as we can,” said Dr. Abla Creasey, VP of Therapeutics Development at CIRM.

https://t.co/9yX6e05Jpi

[Immusoft Corporation @immusoft]

Thanks @Inside_PM for covering our first patient dosed news!

https://t.co/UQdypwu34e

[California Institute for Regenerative Medicine @CIRMnews]

@emilylmullin, from @WIRED, writes:  "@immusoft announced that its scientists have genetically programmed a patient’s B cells and put them back in his body in an effort to treat disease. It’s the first time engineered B cells have been tested in a person." https://t.co/ICS7qD34JW

[Immusoft Corporation @immusoft]

.@FierceBiotech covers our first patient dosed for the world’s first engineered B cell therapy. 🧬🧬🧬

https://t.co/y2KmxqjZ6U

[Julia Moore @juliathiesmoore]

Incredibly proud to announce that Immusoft has dosed the first ever patient with an engineered b cell, and with none of the preconditioning or immunosuppression needed for gene modified stem cells or gene therapy. That's huge.

https://t.co/WCW7BvE1jt

[Precision Oncology News @PrecOncNews]

Immusoft Begins Clinical Trial of Autologous B-Cell Therapy in Mucopolysaccharidosis Type I. ISP-001, which Immusoft developed using its Immune System Programming platform, aims to reprogram patients' B cells so they keep producing alpha-L-iduronidase. https://t.co/AYmkCFeuUk

[Daniel Kraft, MD @daniel_kraft]

Engineering B-cells:

First in human
trial in patient with mucopolysaccharidosis type I

Ex vivo B-cell gene engineering to produce missing enzyme by @immusoft

https://t.co/k8l7xhKoEr

[Chart Westcott @ChartWestcott]

The Westcott family first invested in @immusoft in 2013 when the idea of genetically engineering B-cells (antibody) was just that…an idea. Ten years later, they have dosed their first patient. One day this technology could change millions of lives. We are proud to have played a small part.

https://t.co/B7JU3W8ntR

CC: @VCBrags

#biotech #bcells #VentureCapital

[Latest News from Business Wire @NewsFromBW]

Immusoft Administers the First Engineered B Cell in a Human Clinical Trial https://t.co/VlIJBbLgQZ

[Aurion Biotech @AurionBiotech]

Great companies, in great company! Honored for Aurion to share BioFuture Stage with @endpts @leileiwuu, Sean Ainsworth @Immusoft, Christine Silverstein @ExcisionBio, Liz Wood @JuraBio to talk about the future of cell and gene therapy: how it will transform patient care.

[Alessio D. Nahmad @alessionahmad]

At this year's @ASGCTherapy annual meeting, engineered B cells are shining 🤩
Beautiful abstracts from @PaulaUSC Matthew Porteus, Jennifer Adair, @JustinTaylorLab , @HPKiem , Richard James and David Rawlings, @immusoft and @bebiopharma

[BiotechTechNow @MedTechNow_]

M&A #news

~@immusoft acquires exclusive, worldwide rights to @UMNews's #IP for #genome edited primary B Cells

~#BiminiHealthTech acquires exclusive license to #accellular dermal matrix product portfolio

~@Mindstrong sells #tech assets to @SonderMind

[Immusoft Corporation @immusoft]

Excited to announce we’ve acquired the exclusive worldwide rights to IP for #genomeediting technology for primary B cells. 🧬🧬🧬

Read the full release:

https://t.co/ueeGPJlmR0

[Jason Kraus @Jkraus23]

Genome-editing of primary B cells is becoming increasingly important in this space. It’s exciting to be a scientific advisor to Immusoft, the leader in engineered B cells. @eqxfund @immusoft #proudinvestor https://t.co/sTCvJP3dP8